Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Acquisition Announcement: SpringWorks Therapeutics is being acquired by Merck & Company for $47 per share, totaling an equity value of approximately $3.9 billion, with the deal expected to close in the second half of 2025 pending approvals.
Strategic Benefits: The acquisition will enhance Merck's portfolio in rare tumor treatments and is projected to contribute positively to its revenue and earnings per share by 2027, aligning with Merck's strategy to innovate through selective acquisitions.
Analyst Views on BBP
Wall Street analysts forecast BBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 83.852
Low
Averages
High
Current: 83.852
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
